AR072225A1 - Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos - Google Patents
Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlosInfo
- Publication number
- AR072225A1 AR072225A1 ARP090102313A ARP090102313A AR072225A1 AR 072225 A1 AR072225 A1 AR 072225A1 AR P090102313 A ARP090102313 A AR P090102313A AR P090102313 A ARP090102313 A AR P090102313A AR 072225 A1 AR072225 A1 AR 072225A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl group
- alkyl
- halogen atom
- pirimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Reivindicacion 1: Un derivado de pirimidona representado por la formula (1) o una sal del mismo: donde: X representa un metileno, NH, o un tomo de nitrogeno sustituido con un grupo C(O)-O-(alquilo C1-6); R1 representa un anillo de 2, 3 o 4-piridina o un anillo de 2, 4 o 5-pirimidina, estando el anillo opcionalmente sustituido con un grupo alquilo C1-6, un grupo alcoxi C1-6 o un tomo de halogeno; R2 representa un tomo de hidrogeno, un grupo alquilo C1-6 o un tomo de halogeno; R3 representa un grupo alquilo C1-6, estando este grupo alquilo C1-6 opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un tomo de halogeno, un grupo hidroxilo, un grupo alcoxi C1-6., un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo alquilo C1-6 o un grupo arom tico, y estando el grupo arom tico opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un tomo de halogeno, un grupo hidroxilo, un grupo alcoxi C1-6 o un grupo alquilo C1-6, R4 representa un tomo de hidrogeno, un tomo de halogeno, un grupo hidroxilo o un grupo alquilo C1-6 m representa de 1 a 2 cuando X es un metileno o m representa 2 cuando X es NH, o un tomo de nitrogeno sustituido con un grupo C(O)-O-(alquilo C1-6); en forma de una base libre o de una sal de adicion con un cido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290615A EP2138494A1 (en) | 2008-06-26 | 2008-06-26 | Substituted alkyl pyrimidin-4-one derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072225A1 true AR072225A1 (es) | 2010-08-11 |
Family
ID=39832624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102313A AR072225A1 (es) | 2008-06-26 | 2009-06-24 | Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos |
Country Status (16)
Country | Link |
---|---|
US (1) | US9073914B2 (es) |
EP (2) | EP2138494A1 (es) |
JP (1) | JP5501355B2 (es) |
KR (1) | KR20110027804A (es) |
CN (1) | CN102137861A (es) |
AR (1) | AR072225A1 (es) |
AU (1) | AU2009263850A1 (es) |
BR (1) | BRPI0914759A2 (es) |
CA (1) | CA2728695A1 (es) |
EA (1) | EA201170098A1 (es) |
IL (1) | IL210173A0 (es) |
MX (1) | MX2010014065A (es) |
NZ (1) | NZ590080A (es) |
TW (1) | TW201004953A (es) |
WO (1) | WO2009156864A2 (es) |
ZA (1) | ZA201009272B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138495A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
EP2138485A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138492A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
DK3830092T3 (en) | 2018-08-03 | 2023-08-07 | Novartis Ag | Heteroaromatic nmda receptor modulators and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5170780A (ja) | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinabenzoguanidoruino seiho |
EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
HU178496B (en) * | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
US4304663A (en) * | 1981-01-19 | 1981-12-08 | Manders Logan J | Oil filter apparatus |
US4406897A (en) * | 1981-07-06 | 1983-09-27 | William H. Rorer, Inc. | 6-Aryl-4-hydrazinyl-s-triazin-2-ones |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
EP0861238A4 (en) | 1995-11-01 | 2000-03-01 | Merck & Co Inc | DERIVATIVES OF HEXAHYDRO-5-IMINO-1,4-HETEROAZEPINE INHIBITORS OF NITRIC OXIDE SYNTHASES |
IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
EP1136484A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Arylalkylamino)pyrimidone derivatives |
WO2002087589A1 (fr) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicament permettant d'inhiber une pompe d'elimination de medicament |
BR0212904A (pt) | 2001-09-21 | 2004-10-13 | Sanofi Synthelabo | Derivados substituìdos de 2-pirimidinil-6,7,8,9-tetraidropirimido-{1,2-a}pirimidin- 4-ona e 7-pirimidinil-2,3-diidroimidazo-{1,2-a}pirimi-din-5(1h)-on a para distúrbios neurodegenerativos |
EP1340759A1 (en) * | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
EP1454909B1 (en) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
EP1790649A1 (en) * | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
EP2138492A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
KR101616396B1 (ko) * | 2008-08-11 | 2016-04-28 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
-
2008
- 2008-06-26 EP EP08290615A patent/EP2138494A1/en not_active Withdrawn
-
2009
- 2009-06-24 TW TW098121245A patent/TW201004953A/zh unknown
- 2009-06-24 AR ARP090102313A patent/AR072225A1/es unknown
- 2009-06-25 MX MX2010014065A patent/MX2010014065A/es not_active Application Discontinuation
- 2009-06-25 EP EP09769675.1A patent/EP2321315B1/en active Active
- 2009-06-25 CA CA2728695A patent/CA2728695A1/en not_active Abandoned
- 2009-06-25 NZ NZ590080A patent/NZ590080A/en not_active IP Right Cessation
- 2009-06-25 CN CN2009801335175A patent/CN102137861A/zh active Pending
- 2009-06-25 AU AU2009263850A patent/AU2009263850A1/en not_active Abandoned
- 2009-06-25 KR KR1020117001906A patent/KR20110027804A/ko not_active Application Discontinuation
- 2009-06-25 BR BRPI0914759A patent/BRPI0914759A2/pt not_active IP Right Cessation
- 2009-06-25 WO PCT/IB2009/006568 patent/WO2009156864A2/en active Application Filing
- 2009-06-25 JP JP2011515670A patent/JP5501355B2/ja not_active Expired - Fee Related
- 2009-06-25 EA EA201170098A patent/EA201170098A1/ru unknown
-
2010
- 2010-12-15 US US12/968,868 patent/US9073914B2/en not_active Expired - Fee Related
- 2010-12-22 IL IL210173A patent/IL210173A0/en unknown
- 2010-12-23 ZA ZA2010/09272A patent/ZA201009272B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL210173A0 (en) | 2011-03-31 |
US20110144092A1 (en) | 2011-06-16 |
CA2728695A1 (en) | 2009-12-30 |
JP5501355B2 (ja) | 2014-05-21 |
NZ590080A (en) | 2011-11-25 |
BRPI0914759A2 (pt) | 2015-10-20 |
EP2138494A1 (en) | 2009-12-30 |
KR20110027804A (ko) | 2011-03-16 |
WO2009156864A2 (en) | 2009-12-30 |
CN102137861A (zh) | 2011-07-27 |
EP2321315B1 (en) | 2015-06-03 |
TW201004953A (en) | 2010-02-01 |
ZA201009272B (en) | 2012-03-28 |
US9073914B2 (en) | 2015-07-07 |
AU2009263850A1 (en) | 2009-12-30 |
JP2011525908A (ja) | 2011-09-29 |
EP2321315A2 (en) | 2011-05-18 |
WO2009156864A3 (en) | 2010-04-01 |
MX2010014065A (es) | 2011-05-25 |
EA201170098A1 (ru) | 2011-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072225A1 (es) | Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos | |
AR072224A1 (es) | Derivados de pirimidona sustituidos | |
CY1123308T1 (el) | Αναστολεας ινωσης | |
AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
WO2008155668A3 (en) | Heteroarylamide pyrimidone compounds | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
EA201170093A1 (ru) | Замещенные n-оксидпиразиновые производные | |
MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. | |
AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
RS54202B1 (en) | HINOLINE AND HINOXALINE DERIVATIVE AS KINASE INHIBITORS | |
MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
HN2009000502A (es) | DERIVADOS DE 2- ARIL-6-FENIL-IMIDAZO[ 1,2-a] PIRIDINAS SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
MX336268B (es) | Compuesto de amidina o sal del mismo. | |
AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
EA201170097A1 (ru) | Замещенные трициклические производные против нейродегенеративных заболеваний | |
BR112013024957A2 (pt) | derviado de furanona ou um sal farmaceuticamente aceitável do mesmo | |
TH106984A (th) | อนุพันธ์ n-ออกไซด์ ไพราซีนที่ถูกแทนที่แล้ว | |
TH106984B (th) | อนุพันธ์ n-ออกไซด์ ไพราซีนที่ถูกแทนที่แล้ว |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |